Cancer Family
Malignant Nervous System Neoplasm
CI-CAN-00000246Explore in graph →
953 active trials7 approved drugs131 evidence items
- NCIt
- C4788
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000246Explore in graph →
Clinical trials
3,457 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (495)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03673787 | A Trial of Ipatasertib in Combination With Atezolizumab(IceCAP) | active not recruiting | Phase 1 / Phase 2 | 87 | Institute of Cancer Research, United KingdomOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT05664243 | A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma | active not recruiting | Phase 1 / Phase 2 | 4 | In8bio Inc.INDUSTRY |
| 1 |
| May 1, 2025 |
| clinicaltrials |
| NCT06948994 | A Clinical Trial on Autologous NK Cells Combined With GD2 Monoclonal Antibody in the Treatment of Children With Newly Diagnosed High-risk or Relapsed/Refractory Neuroblastoma | not yet recruiting | Phase 1 / Phase 2 | 15 | Guangzhou Women and Children's Medical CenterOTHER | 0 | Apr 29, 2025 | clinicaltrials |
| NCT06674265 | Safety and Efficacy of Systemic Allogenic NK Cells in R/R Neuroblastoma | recruiting | Phase 1 | 10 | Marzieh EbrahimiINDUSTRY | 1 | Apr 9, 2025 | clinicaltrials |
| NCT06221553 | Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPG(CMD03DIPG) | recruiting | Phase 1 | 9 | Chulalongkorn UniversityOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT06690216 | Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors(PD-L1-PET) | enrolling by invitation | Phase 1 / Phase 2 | 100 | Man HuOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT05034497 | Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases(ReSPECT-LM) | active not recruiting | Phase 1 | 18 | Plus TherapeuticsINDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
| NCT05769660 | A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Temozolomide in Patients with Recurrent or Progressive Glioblastoma Multiforme (GBM) | recruiting | Phase 1 | 12 | BeyondBio Inc.INDUSTRY | 1 | Mar 10, 2025 | clinicaltrials |
| NCT06836505 | Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial. | recruiting | Phase 1 / Phase 2 | 10 | Sun Yat-Sen University Cancer CenterOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT04590664 | Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma | recruiting | Phase 1 / Phase 2 | 24 | Emory UniversityOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06631391 | Phase I Study of Umbilical Cord Blood Natural Killer (NK) Cell Therapy for Children With High-risk, R/R Neuroblastoma. | recruiting | Phase 1 | 30 | Sun Yat-sen UniversityOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT04881032 | AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma(NANO-GBM) | active not recruiting | Phase 1 / Phase 2 | 66 | Centre Jean PerrinOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT01868490 | The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous CIK Cells | enrolling by invitation | Phase 1 / Phase 2 | 20 | Siriraj HospitalOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06751134 | Chimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory Neuroblastoma | recruiting | Phase 1 | 12 | Nanjing Children's HospitalOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT03373097 | Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 42 | Bambino Gesù Hospital and Research InstituteOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT05298995 | GD2-CAR T Cells for Pediatric Brain Tumours | recruiting | Phase 1 | 54 | Bambino Gesù Hospital and Research InstituteOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT06097975 | A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma(NEO-GLITIPNI) | recruiting | Phase 1 | 18 | Universitair Ziekenhuis BrusselOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT04758533 | Clinical Trial to Assess the Safety and Efficacy of AloCELYVIR With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) in Combination With Radiotherapy or Medulloblastoma in Monotherapy(AloCELYVIR) | active not recruiting | Phase 1 / Phase 2 | 13 | Hospital Infantil Universitario Niño Jesús, Madrid, SpainOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT05561374 | Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma | active not recruiting | Phase 1 | 16 | Oblato, Inc.INDUSTRY | 1 | Nov 29, 2024 | clinicaltrials |
| NCT05768919 | Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas | recruiting | Phase 1 / Phase 2 | 30 | SignPath Pharma, Inc.INDUSTRY | 1 | Nov 29, 2024 | clinicaltrials |
| NCT06640582 | TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas(BAH2472) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT01985087 | A Study Using Radiation Therapy and Temozolomide to Treat Glioblastoma in Patients Over 70 | active not recruiting | Phase 1 / Phase 2 | 18 | University of LouisvilleOTHER | 1 | Oct 31, 2024 | clinicaltrials |
| NCT00102648 | Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide | active not recruiting | Phase 1 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT06616727 | The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM | enrolling by invitation | Phase 1 | 50 | Shanghai Simnova Biotechnology Co.,Ltd.INDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06258018 | Niraparib and Temozolomide in Patients Glioblastoma(ONC-2022-001) | not yet recruiting | Phase 1 / Phase 2 | 86 | Armando Santoro, MDOTHER | 1 | Aug 30, 2024 | clinicaltrials |
| NCT04933422 | CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM) | not yet recruiting | Phase 1 | 72 | Crimson Biopharm Inc.INDUSTRY | 0 | Aug 21, 2024 | clinicaltrials |
| NCT06554561 | A Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System Lymphoma | recruiting | Phase 1 / Phase 2 | 43 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT06524063 | Targeted Survivin DC Cell Injection for the Treatment of GBM | not yet recruiting | Phase 1 | 9 | Beijing Tricision Biotherapeutics IncINDUSTRY | 0 | Jul 29, 2024 | clinicaltrials |
| NCT06485908 | Axitinib and Oral Metronomic Etoposide for Pediatric Children and AYA Refractory/Relapsing Medulloblastoma and Ependymoma(MEPENDAX) | not yet recruiting | Phase 1 / Phase 2 | 40 | Assistance Publique Hopitaux De MarseilleOTHER | 0 | Jul 3, 2024 | clinicaltrials |
| NCT06418113 | Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma(GLINERA) | recruiting | Phase 1 | 12 | Hospital San Carlos, MadridOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT05664464 | Glutamate Inhibitors in Glioblastoma(GLUGLIO) | recruiting | Phase 1 / Phase 2 | 120 | University of ZurichOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT05577091 | Tris-CAR-T Cell Therapy for Recurrent Glioblastoma | recruiting | Phase 1 | 10 | Beijing Tiantan HospitalOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06305910 | CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults | recruiting | Phase 1 | 24 | OX2 TherapeuticsINDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05717699 | Oncolytic Virus Ad-TD-nsIL12 for Progressive Pediatric Diffuse Intrinsic Pontine Glioma | recruiting | Phase 1 | 18 | Capital Medical UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT05717712 | Oncolytic Virus Ad-TD-nsIL12 for Primary Pediatric Diffuse Intrinsic Pontine Glioma | recruiting | Phase 1 | 18 | Capital Medical UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT04443010 | Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma(GLIOSUN) | recruiting | Phase 1 / Phase 2 | 226 | Philogen S.p.A.INDUSTRY | 1 | Oct 10, 2023 | clinicaltrials |
Data updated 22 days agoSource updated May 14, 2025source: clinicaltrials